MYO16 and thymoma: Additionally, patients with TCs had a higher frequency of MYO16 mutation (33% vs. 3%, p = 0.024) and a lower frequency of ZNF729 mutation (0% vs. 35%, p = 0.044) than those with thymomas (Figure 3B).